- Home
- CYRX vs ERAS Comparison
CYRX vs ERAS Comparison
Compare CYRX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- ERAS
- Stock Information
- Founded
- CYRX 1999
- ERAS 2018
- Country
- CYRX United States
- ERAS United States
- Employees
- CYRX N/A
- ERAS N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CYRX Health Care
- ERAS Health Care
- Exchange
- CYRX Nasdaq
- ERAS Nasdaq
- Market Cap
- CYRX 310.4M
- ERAS 432.6M
- IPO Year
- CYRX N/A
- ERAS 2021
- Fundamental
- Price
- CYRX $5.55
- ERAS $1.16
- Analyst Decision
- CYRX Strong Buy
- ERAS Strong Buy
- Analyst Count
- CYRX 7
- ERAS 6
- Target Price
- CYRX $11.29
- ERAS $4.83
- AVG Volume (30 Days)
- CYRX 559.3K
- ERAS 2.3M
- Earning Date
- CYRX 05-06-2025
- ERAS 05-07-2025
- Dividend Yield
- CYRX N/A
- ERAS N/A
- EPS Growth
- CYRX N/A
- ERAS N/A
- EPS
- CYRX N/A
- ERAS N/A
- Revenue
- CYRX $228,385,000.00
- ERAS N/A
- Revenue This Year
- CYRX N/A
- ERAS N/A
- Revenue Next Year
- CYRX $5.30
- ERAS N/A
- P/E Ratio
- CYRX N/A
- ERAS N/A
- Revenue Growth
- CYRX N/A
- ERAS N/A
- 52 Week Low
- CYRX $4.58
- ERAS $1.01
- 52 Week High
- CYRX $17.41
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CYRX 46.04
- ERAS 41.47
- Support Level
- CYRX $5.34
- ERAS $1.01
- Resistance Level
- CYRX $5.97
- ERAS $1.29
- Average True Range (ATR)
- CYRX 0.66
- ERAS 0.17
- MACD
- CYRX 0.02
- ERAS 0.00
- Stochastic Oscillator
- CYRX 38.82
- ERAS 31.25
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.